JP6154751B2 - 合成ｌｔａ模倣物、並びにグラム陽性感染症の治療及び／又は予防のためのワクチン成分としてのその使用 - Google Patents

合成ｌｔａ模倣物、並びにグラム陽性感染症の治療及び／又は予防のためのワクチン成分としてのその使用 Download PDF

Info

Publication number
JP6154751B2
JP6154751B2 JP2013557032A JP2013557032A JP6154751B2 JP 6154751 B2 JP6154751 B2 JP 6154751B2 JP 2013557032 A JP2013557032 A JP 2013557032A JP 2013557032 A JP2013557032 A JP 2013557032A JP 6154751 B2 JP6154751 B2 JP 6154751B2
Authority
JP
Japan
Prior art keywords
lta
infections
synthetic
pharmaceutical composition
lipoteichoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013557032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507450A (ja
JP2014507450A5 (https=
Inventor
ヒューブナー，ヨハネス
ヒューブナー−クロペク，アンドレア
ディルク コルネリス コディ，ヨルン
ディルク コルネリス コディ，ヨルン
デア マルエル，ヘイスベルト アリー ファン
デア マルエル，ヘイスベルト アリー ファン
フレデリック ヨハン ホーゲンドルフ，ウーター
フレデリック ヨハン ホーゲンドルフ，ウーター
Original Assignee
ウニベルシタットスクリニクム フライベルク
ウニベルシタットスクリニクム フライベルク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシタットスクリニクム フライベルク, ウニベルシタットスクリニクム フライベルク filed Critical ウニベルシタットスクリニクム フライベルク
Publication of JP2014507450A publication Critical patent/JP2014507450A/ja
Publication of JP2014507450A5 publication Critical patent/JP2014507450A5/ja
Application granted granted Critical
Publication of JP6154751B2 publication Critical patent/JP6154751B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013557032A 2011-03-10 2012-02-17 合成ｌｔａ模倣物、並びにグラム陽性感染症の治療及び／又は予防のためのワクチン成分としてのその使用 Expired - Fee Related JP6154751B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161451304P 2011-03-10 2011-03-10
US61/451,304 2011-03-10
EP20110157947 EP2500349B1 (en) 2011-03-11 2011-03-11 Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections
EP11157947.0 2011-03-11
PCT/EP2012/052801 WO2012119846A1 (en) 2011-03-10 2012-02-17 Synthetic lta mimetics and use thereof as vaccine component for therapy and/or pro-phylaxis against gram-positive infections

Publications (3)

Publication Number Publication Date
JP2014507450A JP2014507450A (ja) 2014-03-27
JP2014507450A5 JP2014507450A5 (https=) 2015-03-12
JP6154751B2 true JP6154751B2 (ja) 2017-06-28

Family

ID=43828266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013557032A Expired - Fee Related JP6154751B2 (ja) 2011-03-10 2012-02-17 合成ｌｔａ模倣物、並びにグラム陽性感染症の治療及び／又は予防のためのワクチン成分としてのその使用

Country Status (6)

Country Link
US (1) US9290531B2 (https=)
EP (1) EP2500349B1 (https=)
JP (1) JP6154751B2 (https=)
CA (1) CA2829126A1 (https=)
ES (1) ES2544808T3 (https=)
WO (1) WO2012119846A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
US10781175B2 (en) 2016-07-15 2020-09-22 Am Chemicals Llc Solid supports and phosphoramidite building blocks for oligonucleotide conjugates
KR101950881B1 (ko) * 2017-08-10 2019-02-22 서울대학교산학협력단 리포테이코익산(Lipoteichoic acid(LTA))을 함유하는 피부 재생 및 창상 치유용 약학 조성물
MX394768B (es) * 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2208780C (en) * 1995-01-30 2010-03-30 Peter Truog Antitumor and anticholesterol preparations comprising lipoteichoic acid lta-t of streptococcus sp dsm 8747
AUPQ137699A0 (en) 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
WO2003066649A1 (en) * 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides

Also Published As

Publication number Publication date
US20140050741A1 (en) 2014-02-20
JP2014507450A (ja) 2014-03-27
EP2500349B1 (en) 2015-05-06
US9290531B2 (en) 2016-03-22
CA2829126A1 (en) 2012-09-13
WO2012119846A1 (en) 2012-09-13
HK1175786A1 (en) 2013-07-12
ES2544808T3 (es) 2015-09-04
EP2500349A1 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
ES2528648T3 (es) Inmunógenos polisacáridos de la Clostridium Difficile
Ravinder et al. A synthetic carbohydrate–protein conjugate vaccine candidate against Klebsiella pneumoniae serotype K2
Zhang et al. Discovery of oligosaccharide antigens for semi‐synthetic glycoconjugate vaccine leads against Streptococcus suis serotypes 2, 3, 9 and 14
JP6154751B2 (ja) 合成ｌｔａ模倣物、並びにグラム陽性感染症の治療及び／又は予防のためのワクチン成分としてのその使用
Naini et al. Semisynthetic glycoconjugate vaccine candidates against Escherichia coli O25B induce functional IgG antibodies in mice
JP5746217B2 (ja) 腸球菌の細胞壁成分及びその抗菌的使用
JP2018537428A (ja) カンピロバクター・ジェジュニに対する合成抗原コンストラクト
US20190282702A1 (en) Polysaccharide and methods
Shen et al. Synthesis of structure-defined β-1, 4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus
JP6230991B2 (ja) エンテロコッカス・フェシウムクローナルコンプレックス１７に由来するラムノ多糖及びその使用
HK1175786B (en) Synthetic lta mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections
Ali et al. Synthetic teichoic acid chemistry for vaccine applications
Santi Synthesis of carbohydrate antigens and their structural analogues for vaccines development
KR20240161137A (ko) 녹농균 감염의 예방/치료
JP6226948B2 (ja) エンテロコッカス・フェカリスの細胞壁高分子及びその使用
Shen Development of Vaccine Candidates Against Emerging Bacteria via Chemical Syntheses of Antigens
Xu Synthetic oligosaccharides as tools to investigate bacterial capsular polysaccharides and teichoic acids
HK40113822A (zh) 预防/治疗铜绿假单胞菌感染
HK1178803B (en) Enterococcal cell wall components and antibacterial use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160330

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160630

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170602

R150 Certificate of patent or registration of utility model

Ref document number: 6154751

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees